Aigner_Andreas Posted - 3 days ago

TD SELL $LH at 210.59, Supp 200.25 Resis 213.21 R6 HiLo 59% T1Y 293 buy 1.9 DIV 1.25% #Laboratory #stocks #trading #finance #market

Chark Posted - 4 days ago

$LH Haven’t looked at this in awhile. The chart looks so ugly I thought it had split. 😂

InsiderPeek Posted - 4 days ago

$LH Chief Legal Officer Van Der Vaart Sandra D sold 2k shares for $421.7k (ownership down 26.19%) insiderpeek.com/company/LH

Stock_Titan Posted - 5 days ago

$LH Labcorp Introduces First Trimester Screening Test to Assess Preeclampsia Risk during Pregnancy https://www.stocktitan.net/news/LH/labcorp-introduces-first-trimester-screening-test-to-assess-mxhmxvezmcqa.html

lowfloatscambuster Posted - 1 week ago

@IOMASS The market is telling you it doesn’t believe that. Every time $LH drops a new adjacent diagnostic test to QTRX, stock gets destroyed- it happened last year around this https://ir.labcorp.com/news-releases/news-release-details/labcorp-launches-new-test-accelerate-path-diagnosis-alzheimers And QTRX management has been woefully inept at managing the message, that is 100% a contributing factor to the EV of this company being a pathetic $300 million. I think they have 6 months MAX left to prove that they can capitalize on the AD oportunity as a standalone company. But if you again hear that diagnostic revs are “immaterial” and not included in guidance when they report Q2 in Aug, look out below. At this point, if there is a strategic offering them $30/shr, they need to take that deal immediately. It’s not out of the question - the technology is real and it can be valuable.

Stock_Titan Posted - 1 week ago

$LH $NVTAQ Invitae Receives Court Approval for Sale to Labcorp https://www.stocktitan.net/news/LH/invitae-receives-court-approval-for-sale-to-huihfjskcx24.html

DonCorleone77 Posted - 2 weeks ago

$LH Geneoscopy to launch ColoSense in collaboration with Labcorp after FDA approval Geneoscopy announced that the U.S. Food and Drug Administration (FDA) approved its noninvasive colorectal cancer screening test, ColoSense. ColoSense is indicated as a screening test for adults, 45 years of age or older, who are at typical average risk for developing CRC. Designated as a Breakthrough Device by the FDA, ColoSense is the first noninvasive colorectal cancer screening test to provide a dynamic view of disease activity by using RNA biomarkers. RNA biomarkers are not subject to age-related methylation patterns that can lead to variability in test performance across different age groups. FDA approval of ColoSense is a significant step in making this important screening tool available to patients. Geneoscopy is working with payors, professional societies, and advocacy partners to support a commercial launch later this year or early in 2025 to ensure patients have timely access to ColoSense to support CRC screening. Geneoscopy will launch ColoSense in collaboration with Labcorp (LH).

Stock_Titan Posted - 2 weeks ago

$LH FDA Approves ColoSense™ – Geneoscopy's Noninvasive Multi-target Stool RNA (mt-sRNA) Colorectal Cancer Screening Test https://www.stocktitan.net/news/LH/fda-approves-colo-sense-geneoscopy-s-noninvasive-multi-target-stool-12jawwubaxg6.html

smartkarma Posted - 2 weeks ago

$LH | Laboratory Corporation of America (LabCorp): Will The Acquisition of Invitae Be A Game Changer? - Major Drivers "Laboratory Corporation of America Holdings (LabCorp) has seen significant growth in its first quarter of 2024 and continues to show promise for..." - Baptista Research (Baptista Research) Key Points:Laboratory Corporation of America Holdings (LabCorp) has seen significant growth in its first quarter of 2024 and continues to show promise for the rest of the year.The total revenue for the quarter was $3.2 billion with adjusted earnings per share at $3.68, which represents a 5% increase in enterprise revenue from the first quarter of 2023.Within the revenue growth, the Diagnostic Laboratories business accounted for a 4% increase, while Biopharma revenue rose 8%. Read more: https://www.smartkarma.com/insights/laboratory-corporation-of-america-labcorp-will-the-acquisition-of-invitae-be-a-game-changer-major-drivers

insiderbuyingselling Posted - 2 weeks ago

$LH new insider selling: 500 shares. http://insiderbuyingselling.com/?t=LH

Lectin_Pectin Posted - 2 weeks ago

$INBS very bullish article here. Great info and synopsis. https://talkmarkets.com/content/stocks--equities/intelligent-bio-solutions-fingerprint-drug-screening-technology-poised-for-massive-growth?post=442811 They might actually give those $LH and $DGX urine tests a run for their money!!

insiderbuyingselling Posted - 2 weeks ago

$LH new insider selling: 2439 shares. http://insiderbuyingselling.com/?t=LH

WhisperNumber Posted - 04/30/24

$CVS #earnings before open Wed, the expectation from the WhisperNumber community is $1.81, 10c ahead of analyst estimates. Earnings came in $0.04 ahead of the whisper last quarter. 58% beat rate. Implied movement +/-4.3%. https://www.whispernumber.com #options $CI $LH

briefingcom Posted - 04/29/24

$LH: Laboratory Corp receives FDA approval for first companion diagnostic for use with Pfizer's (PFE) newly approved gene therapy to treat patients with Hemophilia B https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20240429070728LH&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

DonCorleone77 Posted - 04/29/24

$LH $PFE Labcorp: FDA approves nAbCyte Anti-AAVRh74var HB-FE Assay Labcorp (LH) announced the U.S. FDA has approved its nAbCyte Anti-AAVRh74var HB-FE Assay, a companion diagnostic to determine patient eligibility for treatment with BEQVEZ, Pfizer's (PFE) recently FDA-approved hemophilia B gene therapy. The nAbCyte cell-based neutralizing antibody assay is a component of Pfizer's program to target recombinant adeno-associated virus-based gene therapies to the appropriate patient population. Before infusion with BEQVEZ, patients will require testing for preexisting anti-AAVRh74var antibodies. Labcorp's nAbCyte cell-based neutralizing antibody assay will allow for the accurate detection of preexisting neutralizing antibodies, which could impact patient safety and/or efficacy of the one-time treatment.

Stock_Titan Posted - 04/29/24

$LH Labcorp Receives FDA Approval for First Companion Diagnostic for Use with Pfizer's Newly Approved Gene Therapy to Treat Patients with Hemophilia B https://www.stocktitan.net/news/LH/labcorp-receives-fda-approval-for-first-companion-diagnostic-for-use-lg4gwwht3500.html

Millones Posted - 04/25/24

$LH https://www.reuters.com/markets/deals/clinical-lab-operator-labcorp-buy-bankrupt-genetic-test-maker-invitae-239-mln-2024-04-25/?trk=feed_main-feed-card_feed-article-content

TalkMarkets Posted - 04/25/24

Intelligent Bio Solutions’ Fingerprint Drug Screening Technology Poised For Massive Growth $INBS Also $ABT $DGX $LH $OSUR https://talkmarkets.com/content/stocks--equities/intelligent-bio-solutions-fingerprint-drug-screening-technology-poised-for-massive-growth?post=442811

TalkMarkets Posted - 04/25/24

Intelligent Bio Solutions’ Fingerprint Drug Screening Technology Poised For Massive Growth $INBS Also $ABT $DGX $LH $OSUR https://talkmarkets.com/content/stocks--equities/intelligent-bio-solutions-fingerprint-drug-screening-technology-poised-for-massive-growth?post=442811

AnimalBob Posted - 04/25/24

@tactictrade @mumiok it says assets, doesn’t say anything about shareholders yet. Most likely we don’t get shit. Would be nice to get some shares of $LH 🤣

EBXHoldings Posted - 04/25/24

$LH Been a loser since the covid days......business as usual. Buying up losers to prop up a stagnant business model and employees pay the price in low raises and more multitasking work. Nothing new to see here.

mumiok Posted - 04/25/24

$NVTAQ on X "$LH bought (if approved by the court) $NVTAQ $NVTA for $239M - that's $0.87 per share with 275M shares outstanding, if I count correctly. And Labcorp expects acquired assets to generate ~$300M annualy... It will be interesting to see if they want to keep $550M of NOL and if yes (why not?), is there any way to do this without retaining shareholders..."

DonCorleone77 Posted - 04/25/24

$LH Labcorp narrows FY24 adjusted EPS view to $14.45-$15.35 from $14.30-$15.40 Consensus $14.82. The company said, "Labcorp is updating 2024 full year guidance to reflect its first quarter performance and full year outlook. The following guidance assumes foreign exchange rates effective as of March 31, 2024, for the remainder of the year. Enterprise level guidance includes the estimated impact from currently anticipated capital allocation, including acquisitions, share repurchases and dividends."

DonCorleone77 Posted - 04/25/24

$LH Labcorp reports Q1 adjusted EPS $3.68, consensus $3.48 Reports Q1 revenue $3.18B, consensus $3.12B. "Labcorp's first quarter performance sets a strong foundation for the year ahead," said Adam Schechter, chairman and CEO of Labcorp. "We have a strong position as a partner of choice for health systems and regional/local laboratories, announcing or completing several transactions in the quarter. Additionally, we continue to harness science, technology and innovation as we expand Labcorp's test menu to meet patients' evolving needs. The Labcorp team will build off this momentum and continue to deliver value for customers, shareholders and employees as we further our mission to improve health and improve lives."

epsguid Posted - 04/25/24

$LH reported earnings of $3.68, consensus was $3.46 via @eWhispers #epsbeat http://eps.sh/d/lh

Stock_Titan Posted - 04/25/24

$LH Labcorp Announces 2024 First Quarter Results https://www.stocktitan.net/news/LH/labcorp-announces-2024-first-quarter-llzgrhyzazl8.html

DonCorleone77 Posted - 04/25/24

$LH Labcorp wins bid to purchase assets of Invitae for $239M Labcorp announced that it has been selected as the winning bidder for select assets of Invitae, a medical genetics company. Before the transaction can proceed, the court overseeing the process must issue an approval order following a hearing currently scheduled for May 6, 2024. Upon completion, Labcorp expects this transaction would generate approximately $275M-$300M in annual revenue with the vast majority in specialty testing areas such as oncology and rare diseases. The purchase price for the transaction is $239M. The transaction is anticipated to close in third quarter of 2024, subject to customary closing conditions for a transaction of this type, including applicable regulatory approvals. Through this transaction, Labcorp would acquire assets being auctioned through a voluntary bankruptcy protection process.

DonCorleone77 Posted - 04/24/24

$NVTAQ $LH Invitae enters into agreement with Labcorp for $239M sale of business Invitae (NVTA) announced that Labcorp (LH) has been selected as the winning bidder in the Company's auction in its sale process under Section 363 of the U.S. Bankruptcy Code. Labcorp will acquire substantially all of the Company's assets on a going concern basis for $239 million in cash consideration, plus other non-cash consideration. The hearing to approve the sale is currently scheduled for May 6, 2024. With Court approval, as well as customary regulatory approvals and closing conditions, Labcorp and Invitae anticipate completing the sale process in the third quarter of 2024.

Stock_Titan Posted - 1 month ago

$LH Labcorp Announces First-of-Its-Kind Test for Early Indication of Neurodegenerative Diseases and Brain Injuries Using a Blood Draw https://www.stocktitan.net/news/LH/labcorp-announces-first-of-its-kind-test-for-early-indication-of-9tsy182hil5l.html

DonCorleone77 Posted - 1 month ago

$LH Labcorp receives FDA EUA for Mpox PCR Test Home Collection Kit Labcorp announced today the FDA has granted Emergency Use Authorization, or EUA, for its Mpox PCR Test Home Collection Kit to aid in the diagnosis of infection with non-variola Orthopoxvirus, including the monkeypox virus that causes monkeypox, also known as mpox. The test is the first mpox at-home collection kit authorized by FDA and is available to physicians to order for patients 18 years of age or older who are suspected of mpox infection.